€10.7M
The funding from the Disruptive Technology Innovation Fund will support clinical trials for the CanVas-001 cell therapy candidate.
HL
HAON Life Sciences
Developing regenerative cell therapies to treat neonatal brain injuries.
Ireland—Founded 2022
€10.7MTotal raised
Irish biotechnology startup developing cell-based therapies for infant brain injuries.
Categories
Founders
Mark O’Neill
FCA
Mark brings life sciences and biotechnology financial and executive experience as the founder of HAON Life Science and chief financial officer at Afimmune. He previously served as chief executive officer at DS Biopharma and a business partner at Enterprise Ireland.
LinkedIn
Moayed Hamza
Co-founder
Moayed brings life sciences and medical leadership experience from roles at HAON Life Sciences, Afimmune, and DS Biopharma, alongside business advisory work with Enterprise Ireland.
LinkedIn